Kasiniv

Caspofungin, the active ingredient in Kasiniv, is an echinocandin presented as an intravenous formulation for use in hospitalized patients with serious fungal infections such as invasive candidiasis and aspergillosis. It is administered under medical supervision to treat life‑threatening infections caused by susceptible Candida and Aspergillus species.

GNH USA supplies Kasiniv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Kasiniv (caspofungin) is used to treat invasive fungal infections by targeting the cell wall of susceptible yeasts and molds.

- Invasive candidiasis: effective for bloodstream and deep‑tissue infections caused by Candida species. - Candida auris infections: provides treatment option for this multidrug‑resistant yeast. - Invasive aspergillosis: used in patients with proven or probable aspergillosis when other therapies are unsuitable.

Caspofungin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever: transient elevation of body temperature. - Chills: shaking sensation often accompanying infusion. - Elevated liver enzymes: mild increase in ALT or AST. - Nausea: occasional feeling of stomach upset.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Hepatotoxicity: significant rise in liver enzymes or jaundice. - Severe infusion‑related reactions: hypotension or bronchospasm. - Renal impairment: acute kidney injury in susceptible patients.

When using Kasiniv, clinicians should consider several precautionary measures to ensure safe administration.

- Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: evaluate liver enzymes before initiation and periodically. - Concomitant medications: review for potential interactions, especially with cytochrome P450 substrates. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Infusion monitoring: observe patients for signs of hypersensitivity during and after infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Caspofungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Cytochrome P450 inducers (e.g., rifampin, carbamazepine): may reduce caspofungin exposure. - Strong immunosuppressants (e.g., tacrolimus) combined with high‑dose caspofungin: increased risk of toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may alter plasma levels; monitor clinical response. - Warfarin: potential for altered anticoagulation; check INR regularly. - Diuretics (e.g., furosemide): may affect renal handling; monitor kidney function.